Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rilpivirine

rilpivirine

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of rilpivirine

9 trials tracked of rilpivirine: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 30 citations.

9Trials tracked
4Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 3 Phase 1 1 Other / NA 1
  1. Phase 3 A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women Completed · 30 cited
  2. Phase 4 Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress Completed
  3. Phase 3 A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment Completed
  4. Phase 3 A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 Completed
  5. Phase 2 A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years Completed
  6. Phase 2 A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed Completed
Show 3 more trials
  1. Phase 2 Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis Completed
  2. Phase 1 The Rilpivirine Cerebrospinal-fluid (CSF) Study Completed
  3. N/A Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Long-acting cabotegravir plus rilpivirine noninferior to oral dolutegravir for HIV viral suppression
Infectious Disease RCT
Long-acting cabotegravir plus rilpivirine noninferior to oral dolutegravir for HIV viral suppression Long-acting Injections Show Potential for HIV Treatment Management
This Phase 3b randomized trial of 537 adults with virally suppressed HIV in East and Southern Africa found long-acting cabotegravir plus ril…
A new trial shows that long-acting injections may be as effective as daily pills for keeping HIV suppressed in patients with adherence chall…
Oct 15, 2026
Long-Acting Injections Beat Daily Pills for Teens With HIV
Pediatrics RCT
Long-Acting Injections Beat Daily Pills for Teens With HIV Long Acting Injection Shows Better Viral Suppression for HIV
In a randomized trial of 476 adolescents with HIV, long-acting cabotegravir-rilpivirine injections led to far fewer virological failures tha…
A new long acting injection may help adolescents with HIV maintain viral suppression more effectively than daily oral medication.
Oct 10, 2026
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
Infectious Disease RCT
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy HIV drug resistance patterns vary by region and prior treatment history
This substudy examined HIV-1 drug resistance mutations in people failing first-line therapy across 14 countries.
HIV drug resistance varies by region and prior treatment. Subtype C dominates, but resistance to common drugs is high. This matters for choo…
May 1, 2026